GLP-1– tag –
-
Swiss Bachem Invests Over $431M in 2026 to Meet Surging Global Peptide and Oligonucleotide Demand with New Facility
Pharma Manufacturing Switzerland Overview Bachem, a Swiss CDMO specializing in peptides and oligonucleotides, is undertaking a major manufacturing capacity expansion across its global network, investing between $431 million and $493 mill... -
CDMOs Boost Sterile Fill-Finish and Prefilled Syringe Capacity by Over $1 Billion to Meet Biologics and GLP-1 Drug Demand
BioProcess International USA Overview Contract Manufacturing and Development Organizations (CMOs/CDMOs) are making multi-billion dollar investments, including PCI Pharma Services' global $1 billion expansion, to significantly increase st... -
GLP-1 Review Finds Strongest Signals for GI Adverse Events, Hints at Reduced Infection/Respiratory Risk
GI and Hepatology News USA Overview A systematic review and meta-analysis published in JAMA Network Open found that GLP-1 receptor agonists (GLP-1 RAs) consistently increase gastrointestinal side effects like nausea, vomiting, and diarrh... -
Semaglutide More Than Doubles MASH Resolution Likelihood in Meta-Analysis, Stabilizing Fibrosis
AJMC USA Overview A systematic review and meta-analysis published in Medicine reveals that the GLP-1 receptor agonist semaglutide more than doubles the likelihood of MASH (metabolic dysfunction-associated steatohepatitis) resolution with... -
GLP-1 Receptor Agonist Research Rapidly Expanding Across MASLD–MASH–HCC Continuum: US Leads, China Shows Rapid Growth
Frontiers Switzerland Overview Research on GLP-1 Receptor Agonists (GLP-1RAs) in the context of MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease), MASH (Metabolic Dysfunction-Associated Steatohepatitis), and HCC (Hepatocel... -
Oral GLP-1 Drugs May Quash Brain’s Food Craving Circuit, NIH-Funded Study Suggests Role in Hedonic Eating and Addiction
ScienceDaily USA Overview A study funded by the NIH suggests that newer oral small-molecule GLP-1 drugs, such as orforglipron and danuglipron, may reduce hedonic feeding (eating for pleasure) by affecting a reward circuit in the brain. T... -
First Half 2026 Sees 24 New Small-Molecule Approvals: Pioneering PROTAC Vepdegestrant and Oral GLP-1 Orforglipron Enter Market
Chemexpress China Overview Twenty-four small-molecule drugs received their first global approval in the first half of 2026, with 95.8% being oral dosage forms. Key highlights include the approval of the first commercial PROTAC, vepdegest... -
Eli Lilly’s Retatrutide Emerges as Most Powerful Obesity Drug Yet, Achieves Five Consecutive Positive Phase 3 Readouts in TRIUMPH Program
Drug Discovery News USA Overview Eli Lilly's triple agonist retatrutide has shown positive results in metabolic disease, positioning it as a powerful obesity drug. The company has achieved five consecutive positive Phase 3 readouts acros... -
Eli Lilly’s Triple Agonist Retatrutide Achieves 21-23% Weight Loss in Diabetic and CVD Patients Over 80 Weeks, Nears FDA Submission
BioPharma Dive USA Overview Eli Lilly is preparing to seek FDA approval for its obesity drug retatrutide, a triple agonist targeting GLP-1, GIP, and glucagon receptors. New data from the Triumph-2 and Triumph-3 studies showed average bod... -
Eli Lilly’s Triple G-Agonist Retatrutide Succeeds in Two More Phase III Trials for Obesity and Type 2 Diabetes
GlobalData USA Overview Eli Lilly's GLP-1/GIP/Glucagon (GCG) triple receptor agonist, retatrutide, met primary endpoints in two additional Phase III trials (TRIUMPH-2 and TRIUMPH-3) for type 2 diabetes and obesity patients with establish...
